Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combo Lipid-Lowering Drugs Will Help Drive Cholesterol Market In 2007 – IMS

Executive Summary

Patent losses this year for blockbuster lipid-lowering agents including Merck's Zocor (simvastatin) and Bristol-Myers Squibb's Pravachol (pravastatin) will cause a six percentage point drop in growth in the class in 2007, but the advent of combination therapies are expected to help offset the negative impact, IMS Health projects

You may also be interested in...



Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone

J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection

Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone

J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection

Bristol/Sanofi Push Plavix To Exhaust Generic Supply; Levels Remain Unclear

Bristol-Myers Squibb and Plavix marketing partner Sanofi-Aventis have ramped up promotional efforts for the blockbuster antithrombotic in an effort to exhaust outstanding generic supply as quickly as possible

Related Content

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel